Delivery Order SPE2DB22D1202-SPE2DB25FVLT5
- Not listed
- The Defense Logistics Agency awarded a $8,624.13 delivery order to AmerisourceBergen Drug Corp for Synvisc-One Syringe 6ML, a hyaluronic acid-based intra-articular injection used for osteoarthritis pain management. Issued on September 2, 2025, with completion targeted for September 3, 2025, this firm fixed price delivery order was competitively awarded without set-aside designation. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a delivery order valued at $11,568.32 to AmerisourceBergen Drug Corp for Synvisc-One syringes (6mL) on August 4, 2025, with an ultimate completion date of August 5, 2025. This firm fixed-price delivery order represents a non-competitive set-aside and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Synvisc-One is a hyaluronic acid-based injectable used for knee osteoarthritis treatment, indicating this procurement...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Synvisc-One Syringe 6ML, a hyaluronic acid injection used for knee osteoarthritis treatment. This non-set-aside, competitively awarded contract carries a ceiling value of $11,322.76 under a firm fixed price arrangement, with an ultimate completion date of August 22, 2025. The delivery will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Synvisc-One Syringe 6ML, a hyaluronic acid injection used for knee osteoarthritis treatment. This firm fixed-price delivery order, valued at $3,246.60, was awarded on August 25, 2025, with an ultimate completion date of August 26, 2025. The contract represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $13,608.77 to AmerisourceBergen Drug Corp for the supply of Synvisc-One Syringe 6ML, a hyaluronic acid-based injection used for knee osteoarthritis treatment. This firm fixed-price delivery order, issued on August 19, 2025, with an ultimate completion date of August 20, 2025, represents a direct procurement through AmerisourceBergen's existing indefinite delivery contract vehicle with DLA. The award carried no set-aside designation,...
- The Defense Logistics Agency awarded a $25.2K delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Synvisc-One Syringe 6ML, a hyaluronic acid-based joint injection used for osteoarthritis treatment. This firm fixed-price, non-set-aside contract is scheduled for completion by September 18, 2025, with performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement under the company's existing...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency valued at $10,419.84 for Synvisc-One Syringe 6ML, a hyaluronic acid-based joint injection used to treat osteoarthritis pain. The contract, awarded on June 2, 2025, with an ultimate completion date of June 3, 2025, is a firm fixed price delivery order with no set-aside designation. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This award represents a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Synvisc-One Syringe 6ML, a hyaluronic acid injection used in orthopedic and rheumatological applications. The contract, valued at $14,689.32, is a firm fixed price delivery order with an ultimate completion date of August 1, 2025. This award represents a non-set-aside, competitively awarded contract supporting the federal medical procurement needs of military and veteran healthcare systems....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Synvisc-One Syringe 6ML, a hyaluronic acid injection used for osteoarthritis treatment. Valued at $7,796.10 with a firm fixed price structure, this non-set-aside delivery order is scheduled for completion by August 26, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This award represents a child delivery order under...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on August 6, 2025, for the supply of Synvisc-One Syringe 6ML, a hyaluronic acid injection used for osteoarthritis treatment. This firm fixed price delivery order, valued at $5,019.40, represents a competitive award with no set-aside designation and is scheduled for completion by August 7, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FVLT5Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,808.18 to AmerisourceBergen Drug Corp for Synvisc-One Syringes (6mL), a hyaluronic acid-based injectable treatment for osteoarthritis. This firm fixed-price, competitively awarded delivery order was issued on September 18, 2025, with an ultimate completion date of September 19, 2025, and will be performed at the awardee's corporate office in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating it was awarded through open competition. This delivery order represents a task issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a prime pharmaceutical vendor, AmerisourceBergen Drug Corp supplies a comprehensive range of medications and medical devices to support military healthcare programs globally, serving customers including the Defense Health Agency and U.S. Coast Guard. The company's significant presence in federal pharmaceutical procurement reflects its established capability to meet the Department of Defense's medical supply requirements across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.8k | 9/18/25 |